Jonathon S. Berek

Bio: Jonathon S. Berek is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Serous fluid & Serous cystadenocarcinoma. The author has an hindex of 2, co-authored 2 publications receiving 33 citations. Previous affiliations of Jonathon S. Berek include Fox Chase Cancer Center.

Conclusions and recommendations from the Helene Harris Memorial Trust SixthBiennial International Forum on Ovarian Cancer, May 10–14, 1997, LosAngeles, California, USA

Abstract: Sharp F, Blackett AD, Berek JS, Bast RC, Jr. Conclusions and recommendationsfrom the Helene Harris Memorial Trust Sixth Biennial International Forum onOvarian Cancer, May10–14, 1997, Los Angeles, California, USA. Int J Gynecol Cancer 1997; 7: 416–424. The Sixth Biennial International Forum on Ovarian Cancer was held by theHelene Harris Memorial Trust in Los Angeles, California, USA in May 1997. Themain research findingsreported at the forum, together with the conclusions drawn and recommendationsmade by the assembled experts, are presented here as a series of short points.While most aspects ofovarian cancer research and treatment are covered, the points are groupedtogether into topics considering: the genetic basis of ovarian cancer, itsmolecular biology, analyticalapproaches to diagnosis and management, gene therapy approaches, methodologyfor dose intensification, new drugs, quality of life, and ethical issues.

Epithelial Ovarian Cancer

Abstract: Chapter Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189 Primary Chemotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190 Early-Stage Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190 Advanced-Stage Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191 Neoadjuvant Chemotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192 Intraperitoneal Chemotherapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194 Consolidation Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195 Therapeutic Strategies for Recurrent Ovarian Cancer . . . . . . . . . . . . . 196 Definitions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196 Salvage Chemotherapy for Platinum-Sensitive Disease. . . . . . . . . . 197 Salvage Chemotherapy for Platinum-Refractory or Platinum-Resistant Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199 Hormonal Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201 High-Dose Chemotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202 Key Practice Points . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203 Suggested Readings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203

Peritoneal Implants of Ovarian Serous Borderline Tumors: Histologic Features and Prognosis

Abstract: The clinicopathologic features of 56 cases of ovarian serous borderline tumors (SBT) associated with peritoneal implants were reviewed. Data from 368 person-years of follow-up (median follow-up, 6.0 years) were analyzed to investigate the possibility that the histologic features of implants of this type of tumor may correlate with the prognosis. Eighty-five percent of the 56 patients were clinically free of tumor at the time of death or at last contact. Thirteen percent of the patients died of tumor, and one patient (2%) was alive with widespread progressive tumor. The product-limit estimate of the probability of death from tumor (+/- standard error) was 4% (+/- 3%) at 5 years and 23% (+/- 9%) at 10 years. The following three histologic features of the implants correlated with an adverse prognosis: (1) invasion (P = 0.0004), (2) severe cytologic atypia in both invasive and noninvasive implants (P = 0.0008) and in noninvasive implants alone (P = 0.02), and (3) the presence of mitotic activity in both types of implants (P = 0.02) and in noninvasive implants alone (P = 0.02). The only other feature that correlated with the prognosis was the presence of residual tumor postoperatively as assessed by the surgeon (P = 0.01). The product-limit estimate of death of tumor in patients with at least one of these four adverse prognostic factors was 56% (+/- 20%) at 10 years. Whether or not the patients received radiation therapy, chemotherapy, or both had no statistically significant effect on the outcome. These data and the results of a stratified analysis suggest that patients may benefit from additional therapy if adverse prognostic factors are present, especially invasiveness or severe cytologic atypia. It is unlikely that additional therapy is necessary in patients without adverse prognostic features, because no deaths occurred in this group.

Primary psammocarcinoma of the peritoneum.

Abstract: Psammocarcinoma is a rare type of serous carcinoma arising from the ovaries or the peritoneum. Histopathologically, it has large deposits of psammoma bodies, invasion to surrounding tissues, and low-grade cytologic atypia. Biologic behavior is similar to borderline serous tumors with a favorable survival time. Primary surgical debulking with complete resection of the tumor should be the main surgical approach, while the benefit of postoperative chemotherapy remains unknown. A new case of primary peritoneal psammocarcinoma with survival after an initial diagnosis of 5.5 years is presented with a literature review.